Drug Hunter
SEPTEMBER 17, 2023
This month features many of the big reveals from the ACS fall 2023 first disclosures including Nurix’s BTK degrader and RAPT’s CCR4 autoimmune therapy. Several of the molecules making the August list are in Ph. III clinical trials such as Vertex’s sodium channel inhibitor for acute pain and Denali Therapeutics’ CNS-penetrant eIF2B activator for ALS.
ProRelix Research
SEPTEMBER 17, 2023
The rising prevalence of ophthalmology disorders such as dry eye disease (DED) and vision-related issues is largely related to the increasing use of mobile phones, tablet screens, and laptops. Since […] The post Ophthalmology disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drugs.com
SEPTEMBER 17, 2023
SUNDAY, Sept. 17, 2023 -- Cannabinoid products may interfere with some prescription medications, so people who use them should add these to the list of supplements they tell their doctors about. This interference could have serious health.
Science Daily: Pharmacology News
SEPTEMBER 17, 2023
It takes over the brains of ants, causing them to cling to blades of grass against their will. The lancet liver fluke has an exceptional lifecycle strategy, in which snails, ants and grazing animals are unwitting actors. Researchers now reveal more about the mind-bending workings of this tiny parasite.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
FDA Law Blog: Biosimilars
SEPTEMBER 17, 2023
By Philip Won & Véronique Li, Senior Medical Device Regulation Expert — Over the last three and a half years, meetings with FDA were conducted virtually. During this time, CDRH moved from Webex to Zoom and gained experience with the virtual platform. Now, in addition to engaging with FDA via Zoom, medical device sponsors can once again engage in in-person meetings with the Agency.
SCIENMAG: Medicine & Health
SEPTEMBER 17, 2023
ANN ARBOR, Mich. – As smoke from Canada’s historic wildfires triggers poor air quality alerts across the country, many parents worry about the impact on their child’s health, a new national poll suggests. Credit: University of Michigan Health C.S. Mott Children’s Hospital National Poll on Children’s Health ANN ARBOR, Mich.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
SCIENMAG: Medicine & Health
SEPTEMBER 17, 2023
The early treatment of obesity in children is effective in both the short and long term, researchers from Karolinska Institutet report in a study published in The International Journal of Obesity.
Drugs.com
SEPTEMBER 17, 2023
PLAINSBORO, N.J., September 13, 2023 – Effective today, a $35.00 insulin option called MyInsulinRxTM is available from Novo Nordisk Inc for eligible patients. The program builds on existing Novo Nordisk insulin affordability options and is.
SCIENMAG: Medicine & Health
SEPTEMBER 17, 2023
Barcelona, Spain: Bystanders are less likely to give cardiopulmonary resuscitation (CPR) to women than men, particularly if the emergency takes place in a public area, according to research presented at the European Emergency Medicine Congress today (Monday) [1].
Common Sense for Drug Policy Blog
SEPTEMBER 17, 2023
Co-Involvement of Stimulants and Fentanyl in Drug-Related Deaths in the US, 2010-2021 "Findings "The percent of US overdose deaths involving both fentanyl and stimulants increased from 0.6% ( n = 235) in 2010 to 32.3% (34 429) in 2021, with the sharpest rise starting in 2015. In 2010, fentanyl was most commonly found alongside prescription opioids, benzodiazepines, and alcohol.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
SEPTEMBER 17, 2023
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharma companies have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
Common Sense for Drug Policy Blog
SEPTEMBER 17, 2023
Decriminalization of Possession and Low Threshold Limits "The study’s findings emphasize that although some participants expect decriminalization to result in positive outcomes and felt as though the 2.5g threshold was appropriate, the majority of participants foresaw a number of significant limitations due to the defined threshold quantity. Our findings offer insights into what those limitations are.
Common Sense for Drug Policy Blog
SEPTEMBER 17, 2023
Police Attitudes, Enforcement, and Decriminalization of Possession "Our study also underscores the importance of recognizing the long history of uncertainty, punitive actions, and negative experiences with police among people who use drugs. Decriminalization in BC and implementation among police has important implications regarding building trust between people who use drugs, the community, and law enforcement.
Expert insights. Personalized for you.
206 
Let's personalize your content